Not exact matches
The primary endpoint of death and non-fatal heart attack at 30
days was no different between the two
groups (7 percent
in the aspirin
group and 7.1 percent
in the
placebo group); however, major bleeding was significantly higher
in aspirin - treated patients
than in the
placebo group (4.6 percent vs. 3.7 percent).
By the end of treatment, the odds of experiencing a heavy drinking
day in the
placebo group was five times more
than that of the topiramate
group; and the number of patients who experienced no heavy drinking
days on the last four weeks of treatment
in the topirmate
group was more
than double that of the
placebo group.
In one study, subjects who experienced social rejection and who received acetaminophen every
day for three weeks reported fewer hurt feelings
than the
group who received the
placebo.
The mean total number of drinks consumed during the 12 week trial was lower
in the fluoxetine
group than in the
placebo group (70 v 216, p < 0.03) as was the mean number of
days on which alcoholic drinks were consumed during the trial (11 v 20, p < 0.05).